EORTC Bladder Cancer
Calculate NMIBC recurrence and progression risk using the validated EORTC scoring system. Based on Sylvester et al. 2006 pooled analysis of 2,596 patients across seven EORTC trials.
About This Calculator
The EORTC (European Organisation for Research and Treatment of Cancer) Bladder Cancer Recurrence and Progression Risk Calculator predicts the probability of recurrence and progression in patients with non-muscle invasive bladder cancer (NMIBC) over 1 and 5 years. This validated scoring system helps urologists and oncologists tailor adjuvant therapy and surveillance based on individual patient risk.
The calculator evaluates six clinical and pathological factors — number of tumors, tumor diameter, prior recurrence rate, T category (Ta vs T1), presence of concomitant carcinoma in situ (CIS), and tumor grade per the WHO 1973 classification (G1, G2, G3). Each factor contributes weighted points toward separate recurrence and progression scores (0-17 and 0-23 respectively). These scores map to four risk categories — Low, Intermediate, High, and Very High — with corresponding probability percentages derived from a pooled analysis of 2,596 patients across seven EORTC trials published by Sylvester et al. in European Urology (2006).
The results inform treatment decisions per the European Association of Urology (EAU) 2022 guidelines on NMIBC. Low-risk patients typically receive a single postoperative instillation of chemotherapy. Intermediate-risk patients benefit from intravesical chemotherapy or BCG immunotherapy. High-risk and very high-risk patients generally receive intravesical BCG for 1-3 years, with consideration for early cystectomy in very high-risk cases due to the significant progression risk.
Important Clinical Caveats
This calculator is designed for non-muscle invasive bladder cancer (NMIBC) — stages Ta and T1 only. It should not be applied to muscle-invasive disease (T2+). The scoring system was developed from clinical trial data and may not fully reflect outcomes in real-world, unselected populations. All risk assessments should be interpreted by a qualified urologist or oncologist as part of a comprehensive clinical evaluation. The calculator uses the WHO 1973 grading system (G1-G3); if using the WHO 2004/2016 grading system (low-grade/high-grade), note that high-grade corresponds approximately to G3.
Frequently Asked Questions
What is the EORTC bladder cancer risk calculator?
The EORTC bladder cancer recurrence and progression risk calculator is a validated scoring tool that predicts the probability of tumor recurrence and progression in patients with non-muscle invasive bladder cancer (NMIBC) over 1 and 5 years. It uses six clinical and pathological factors from the EORTC risk tables published by Sylvester et al. in 2006.
What factors does the EORTC bladder cancer calculator use?
The calculator evaluates six factors: number of tumors (single, 2-7, or ≥8), tumor diameter (<3 cm or ≥3 cm), prior recurrence rate (primary, ≤1/year, or >1/year), T category (Ta or T1), presence of concomitant carcinoma in situ (CIS), and tumor grade (G1, G2, or G3 per WHO 1973 classification).
How is the EORTC bladder cancer score calculated?
Each of the six factors contributes points toward separate recurrence and progression scores. Recurrence points range from 0-17; progression points range from 0-23. Total scores map to risk categories — Low, Intermediate, High, or Very High — each with corresponding 1-year and 5-year probability percentages derived from a pooled analysis of 2,596 patients across seven EORTC trials.
What is a high-risk EORTC bladder cancer score?
A recurrence score of 5-9 points indicates high risk (38% at 1 year, 62% at 5 years), while 10-17 points indicates very high risk (61% at 1 year, 78% at 5 years). For progression, 7-13 points is high risk (5% at 1 year, 17% at 5 years) and 14-23 points is very high risk (17% at 1 year, 45% at 5 years).
Is this calculator suitable for muscle-invasive bladder cancer?
No. This EORTC risk calculator is designed specifically for non-muscle invasive bladder cancer (NMIBC) — stages Ta and T1. It should not be used for muscle-invasive bladder cancer (stage T2 or higher), which requires different staging and treatment approaches.
What is the difference between recurrence and progression in NMIBC?
Recurrence refers to the return of a bladder tumor at the same or lower stage after initial treatment. Progression refers to the advancement of the disease to a higher stage or grade, including progression to muscle-invasive disease (T2+), which significantly worsens prognosis. The EORTC calculator provides separate risk estimates for both outcomes.
How are EORTC risk scores used in treatment planning?
The EORTC risk category guides adjuvant therapy decisions per EAU guidelines. Low-risk patients may receive a single postoperative instillation of chemotherapy. Intermediate-risk patients benefit from intravesical chemotherapy or BCG. High-risk and very high-risk patients typically require intravesical BCG therapy for 1-3 years, with consideration for early cystectomy in very high-risk cases.
What grading system does the EORTC calculator use?
The original EORTC risk tables use the WHO 1973 grading system (G1, G2, G3). G1 is well-differentiated (low grade), G2 is moderately differentiated, and G3 is poorly differentiated (high grade). Only G3 contributes additional progression points in the scoring system.